CD47-SIRPα-targeted therapeutics: status and prospects.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• CD47 is a transmembrane protein overexpressed on tumor cells, acting as a "don't eat me" signal to inhibit phagocytosis by immune cells.
• The CD47-SIRPα axis is a critical pathway for immune evasion by cancer cells, making it a significant therapeutic target.
• Preclinical studies demonstrate the potential of blocking the CD47-SIRPα interaction to enhance anti-tumor immunity.

Purpose of the Study:

• To review the therapeutic potential of targeting the CD47-SIRPα pathway in cancer treatment.
• To discuss the development and clinical progress of agents blocking CD47 or SIRPα.
• To evaluate the efficacy and safety of CD47-SIRPα blockade in combination therapies.

Main Methods:

• Review of preclinical data and clinical trial findings for CD47-blocking agents.
• Analysis of combination strategies involving CD47-SIRPα blockade with other immunotherapies or standard treatments.
• Assessment of adverse events, particularly anemia, and mitigation strategies.

Main Results:

• Therapeutic antibodies and fusion proteins targeting CD47 or SIRPα have shown preclinical activity against hematologic and solid tumors.
• Anemia, a known side effect, has been managed effectively with strategies like low-dose priming.
• Early clinical studies of combination therapies, including Magrolimab, show promising response rates and good tolerability.

Conclusions:

• CD47-SIRPα blockade represents a promising novel therapeutic approach in oncology.
• Combination strategies are key to overcoming the limitations of single-agent therapy and improving clinical efficacy.
• Ongoing clinical trials will define the role of CD47-SIRPα blockade in standard cancer treatment protocols.